首页> 美国卫生研究院文献>Therapeutics and Clinical Risk Management >Automated estimated GFR reporting: A new tool to promote safer prescribing in patients with chronic kidney disease?
【2h】

Automated estimated GFR reporting: A new tool to promote safer prescribing in patients with chronic kidney disease?

机译:自动估算的GFR报告:一种新的工具可促进慢性肾脏病患者更安全地开处方?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A number of drugs rely on the kidney for excretion and thus require their dose to be modified in any patients where there is renal impairment. Others are nephrotoxic and should be avoided completely in patients with renal disease. Traditionally clinicians have had to rely on serum creatinine to assess renal function but this may not accurately reflect the kidney function of an individual since its level also depends on muscle mass. In particular elderly females may have significant impairment of renal function despite a normal or near normal serum creatinine. The advent of automated reporting of estimated glomerular filtration rate (eGFR) provides the clinician with simple, easily understood and readily available measurement which more accurately reflects a patient’s renal function. In particular eGFR allows the clinician to readily identify and stratify patients with chronic kidney disease (CKD) and can allow a more rational and safer approach to prescribing in this group of high risk patients. This commentary suggests that national prescribing formularies should use eGFR to provide consistent advice about the appropriate dose adjustment and avoidance of potentially toxic drugs at various stages of CKD. Such an approach may prove invaluable in improving prescribing in CKD and avoiding drug toxicity in this group of patients.
机译:许多药物依赖肾脏排泄,因此在有肾功能不全的任何患者中都需要调整其剂量。其他具有肾毒性,在肾病患者中应完全避免。传统上,临床医生不得不依靠血清肌酐来评估肾功能,但这可能无法准确反映个体的肾功能,因为其水平也取决于肌肉质量。特别是老年女性,尽管血清肌酐正常或接近正常,肾脏功能仍可能明显受损。估计肾小球滤过率(eGFR)的自动报告的出现为临床医生提供了一种简单,易于理解且易于获得的测量方法,可以更准确地反映患者的肾功能。特别地,eGFR使临床医生能够轻松地识别慢性肾脏病(CKD)患者并对其进行分层,并且可以为这种高风险患者开出更合理,更安全的处方方法。该评论建议国家处方药应使用eGFR,以就CKD各个阶段的适当剂量调整和避免潜在毒性药物提供一致的建议。这种方法在改善CKD处方和避免该组患者的药物毒性方面可能具有不可估量的价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号